European Commission approves NewAmsterdam/Menarini obicetrapib therapies
European Commission approval granted for NewAmsterdam Pharma’s obicetrapib monotherapy (Ubeslo®) and obicetrapib plus ezetimibe fixed-dose combination (Evlarco®), per TradingView News.